Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT01754376
Title Combined BRAF-Targeted Therapy and Immunotherapy for Melanoma
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Massachusetts General Hospital



Aldesleukin + Vemurafenib

Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Massachusetts General Hospital Boston Massachusetts 02113 United States Details
Beth Israel Deaconess Medical Center Boston Massachusetts 02215 United States Details
*Shaded cells indicate that there was no data available from for the field